Tykerb 泰立沙 Lapatinib 拉帕替尼

Lapatinib is an oral, small-molecule tyrosine kinase inhibitor primarily used for the targeted treatment of HER2-positive breast cancer, often in combination with chemotherapy or other drugs. It inhibits tumor cell growth and spread by blocking the HER2 and EGFR signaling pathways. It is indicated for second-line treatment of advanced or metastatic breast cancer, particularly in patients resistant to other treatment options.

I. Indications and Mechanism of Action
Indications: 1.
Combined with capecitabine for the treatment of HER2-positive advanced or metastatic breast cancer (after failure of other treatments).
Combined with letrozole for postmenopausal women with HER2-positive and hormone receptor-positive metastatic breast cancer.
Mechanism of Action: 2.
Inhibits the tyrosine kinase activity of HER2 (human epidermal growth factor receptor 2) and EGFR (epidermal growth factor receptor), blocking downstream signaling and preventing tumor cell proliferation.
Unlike trastuzumab (Herceptin), lapatinib is a small molecule drug that can penetrate the blood-brain barrier and may be effective for brain metastases. II. Usage and Precautions
Dosage: 1.
Usually, take orally once daily on an empty stomach (1 hour before or 2 hours after meals).
The dosage should be adjusted based on concomitant medications and should be strictly followed according to your doctor’s instructions.
Common Side Effects: 2.
Gastrointestinal reactions (diarrhea, nausea, vomiting), rash, hand-foot syndrome, fatigue, etc.
May cause cardiotoxicity; regular monitoring of electrocardiogram (ECG) and left ventricular ejection fraction is required.
Contraindications and Precautions: 3.
Contraindicated in patients with allergies to drug components.
Careful evaluation is required in patients with severe hepatic or renal impairment, or during pregnancy or lactation.
III. Drug Interactions and Storage
Interactions: 1.
Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampicin) may affect blood drug concentrations, requiring dose adjustment.
Avoid concomitant use with proton pump inhibitors (e.g., omeprazole), as this may reduce drug efficacy.
Storage: 2.
Store at room temperature (20-25°C) away from light and moisture. IV. Medical Guidance and Risk Warnings
Lapatinib is a prescription drug and should be used under the guidance of an oncologist. Do not adjust the dose or discontinue the drug on your own.
Regular follow-up checks of liver, kidney, and heart function, as well as tumor progression, are required during treatment. If severe diarrhea, difficulty breathing, or chest pain occur, seek medical attention immediately.
Lapatinib offers an important treatment option for patients with advanced breast cancer. However, a customized treatment plan should be tailored to the individual’s condition and physician’s advice to ensure safety and effectiveness.